Introduction {#S1}
============

Hiccup (Latin, singultus) is generated by an involuntary contraction of the diaphragm followed by closure of the glottis. The inspired air meeting a closed glottis causes the typical hiccup sound. Hiccupping of extended duration can be incapacitating ([@B91]).

Most classifications use arbitrary time limits to categorize the phenomenon. Brief episodes of hiccupping are physiologic. The point of transition to a pathologic form is not well defined. The longer the duration of the hiccupping, the less amenable it will be to interventions. An episode lasting longer than a week is considered chronic while resistance to sequential therapy using three different drugs warrants the use of the label obstinate ([@B91]).

Hiccup is not a disease but a symptom. The situation most commonly encountered is that of hiccup of idiopathic origin. In this context, "idiopathic" describes one's inability to demonstrate, rather than the absence of, an organic origin.

Probably only a few drugs in the **Physician's Desk Reference** have not been tried in the therapy of singultus, and anyone who looks hard enough at the literature will be able to find anecdotal support for the use of almost any drug. In contrast, only a few drug categories (benzodiazepines, barbiturates, alcohol, and steroids) are well-established hiccup inducers ([@B91]).

Prevalence of chronic obstinate singultus was estimated in Germany in the 1990s at 1:10^3^--1:10^5^, with an overwhelming elderly male preponderance ([@B92]).

Hiccups and Dopamine {#S1.SS1}
--------------------

The introduction of chlorpromazine into clinical practice in the early 1950s had a major impact on psychiatry. The drug revolutionized the discipline and established the field of psycho-pharmacology ([@B72]; [@B10]). The success of chlorpromazine as an antipsychotic (neuroleptic) combined with the fact that it was far superior to the (very) few other central nervous system (CNS) drugs available at the time (morphine, hyoscine, and quinidine) led to its use for a multitude of conditions ([@B37]).

One of the conditions chlorpromazine was tested for was chronic (obstinate) hiccup, and positive case results were reported by various groups ([@B83]; [@B124]; [@B29]; [@B39]; [@B44]; [@B51]).

The manufacturer Smith Kline and French advertised "*another dramatic use of Thorazine: to stop intractable hiccups (often after the first dose) in 56 out of 62 patients in seven different studies,"* and the United States Food and Drug Administration (FDA) approved chlorpromazine for the treatment of hiccups ([@B129], [@B130]).

Chlorpromazine established itself as a successful hiccup treatment, even after attributing some of the reported success rate to a difficult-to-quantify placebo effect ([@B40]).

While chlorpromazine efficacy for chronic hiccup treatment is generally accepted, the mechanism of action is unclear and not necessarily identical with the antipsychotic mechanism of action. Chlorpromazine has a rich pharmacology with at least if not greater affinity for a range of other targets.

This promiscuity is the basis for many of the therapeutic effects and adverse drug reactions (ADRs) of this drug. The antipsychotic usefulness of the drug is related to its ability to block dopamine and serotonin (5-HT) receptors. Among the more relevant ADRs to be named are orthostatic hypotension (α-adrenergic blockade), dry mouth, urinary retention, and other signs and symptoms of parasympathetic inhibition (muscarinic cholinergic blockade), Parkinson's-like symptoms, decrease in libido and increase in plasma prolactin levels (dopaminergic blockade), sedation and weight gain (histaminergic blockade), weight gain, and anhedonia (5-HT~2C~ serotonergic blockade), and QT prolongation (inhibition of the *human ether-a-go-go-related gene* = hERG potassium channel). While the affinity of chlorpromazine for hERG channels is low (high K~i~), the ability to block other sites and induce ADRs is comparable or even higher than its affinity for the sites associated with the *antipsychotic* response.

The assumption that dopamine receptor blockers must be the pillar for treatment of hiccups is---at least partially---based on circular thinking: chlorpromazine is FDA-approved for hiccups, chlorpromazine is a typical neuroleptic, neuroleptics are dopamine receptor blockers, and therefore hiccup is a manifestation of dopaminergic dysfunction.

Evidence for Dopaminergic Involvement {#S1.SS2}
-------------------------------------

1.  Reports of dopaminergic agents (*amantadine, levodopa, pergolide, piribedil*, and *pramipexole*) inducing hiccups ([@B74]; [@B9]; [@B116]).

2.  Reports of selective anti-dopaminergic agents (*haloperidol*) being able to control hiccups ([@B68]; [@B111]; [@B60]).

Evidence Against Dopaminergic Involvement {#S1.SS3}
-----------------------------------------

1.  Reports of failure of anti-dopaminergic agents to control hiccups ([@B113]).

2.  Reports of anti-dopaminergic agents (*perphenazine*) inducing hiccups ([@B82]; [@B24]).

3.  Reports of dopaminergic agonists (*amantadine, apomorphine, pergolide, pramipexole, piribedil, levodopa, ropinrole*) used to treat hiccup ([@B132]; [@B45]; [@B6]; [@B78]; [@B116]; [@B75]; [@B46]; [@B26]).

4.  Reports of failure of selective anti-dopaminergic agents (*haloperidol*) to control hiccups ([@B86]).

5.  Discrepancies between the incidence of use of dopaminergic agonists and the incidence of hiccup, although these might be due to underreporting ([@B123]; [@B81]).

Taken together, the evidence indicates that while an involvement of dopamine as a neurotransmitter in the hiccup reflex circuitry is certain, it is by no means clear that dopaminergic overactivity is the common denominator of hiccups, and therefore dopaminergic blockade must not necessarily be the main thrust of therapeutic attempts.

Non-dopaminergic Therapies of Hiccup {#S1.SS4}
------------------------------------

Hiccupping is a physiologic occurrence during intrauterine life ([@B80]). It has been proposed that hiccup is an essential and universal primitive reflex that may recur, like other primitive reflexes, in adult life ([@B59]; [@B35]; [@B41]; [@B122]). The suggested hiccup reflex arc consists of vagal, phrenic, and sympathetic afferents, a hiccup center in the upper spinal cord/brainstem region, and efferents that elicit a contraction of the diaphragm and the external intercostal muscles along the phrenic and intercostal nerves, as well as, immediately thereafter, a closure of the glottis via the vagus nerve, whose motor fibers travel with the recurrent laryngeal nerve to the larynx ([@B7]; [@B40]; [@B122]).

In the adult, this primitive reflex is suppressed ([@B88]; [@B125]). Reappearance is explained either by the loss of inhibition from hierarchically higher structures or by a surge in input from the periphery.

Many therapeutic strategies, with the GABA~*B*~ receptor agonist baclofen and the α~*2*~-δ ligands (gabapentin, pregabalin) being the most successful ones ([@B18]; [@B73]; [@B104]; [@B50]; [@B93], [@B94]; [@B90]; [@B61]), non-specifically reduce neurotransmitter release; their unquestionable success in chronic hiccup treatment does not, however, allow any inference as to the specific neurotransmitters and their receptors involved in the assumed hiccup reflex circuitry (black-box approach).

More contributory to the understanding of the pathophysiology is a look at therapies empirically established for the suppression of the so-called occasional or transient hiccup. These have recently been reviewed, and the author concludes that the common denominator of most, if not all of these homegrown remedies is their ability to activate the vagus nerve, as evidenced by their additional ability to terminate paroxysmal supraventricular tachycardias ([@B95], [@B96], [@B99]). Among the best-known "vagal maneuvers" are the oculo-cardiac reflex (Dagnini-Aschner), carotid sinus massage, the Valsalva maneuver, and ice ingestion. While usually effective in terminating bouts of acute hiccup, they are mostly ineffective in cases of hiccupping that have been present for an extended period, probably due to insufficiently sustained vagus nerve activation ([@B96]). The successful use of vagus nerve electrical stimulation for chronic intractable hiccups has been reported ([@B89]; [@B76]) as have been failures of this approach ([@B49]). The rationale for stimulating the left vagus nerve is that it innervates the AV node of the heart so as to have less of an effect on heart rate than the right vagus, which innervates the SA node ([@B20]).

Nuclei of the Vagus Nerve {#S1.SS5}
-------------------------

**Nucleus tractus solitarius** (NTS) receives general visceral afferent information. According to Jordan "*the NTS can be considered the brainstem equivalent of the dorsal horn*" ([@B62]). The NTS is involved in a number of reflex mechanisms (gag, carotid sinus, cough, and vomiting reflex).

**Nucleus ambiguus** (NA) is in the medullary reticular formation. The nerve fibers originating from the NA are efferent visceral motor fibers that provide motor innervation for swallowing and phonation. This vagal nucleus innervates most striated muscles of the pharynx and larynx. The NA also contains the majority (≈90%) of preganglionic cholinergic parasympathetic neurons that innervate postganglionic parasympathetic neurons in the heart.

**Dorsal vagal nucleus** (DVN) sends parasympathetic visceral efferent fibers to thoracic and abdominal viscera.

The activation of cardiac vagal outflow by afferents involves a multi-synaptic pathway within the brainstem. Cardiorespiratory afferents terminate within the NTS. Neurotransmitters used by vagal afferents include peptides such as substance P and calcitonin gene-related peptide and the excitatory amino acid transmitter glutamate ([@B20]). Within this nucleus, the information is processed and integrated before passing to the output neurons located within the DVN and NA ([@B118]; [@B62]).

Influence of Serotonin (5-HT) Upon Autonomic Nervous System Activity {#S1.SS6}
--------------------------------------------------------------------

5-HT interacts with the autonomic nervous system, in particular its parasympathetic component (vagus nerve) at several levels.

Intravenous administration of 5-HT lowers the heart rate. Since 5-HT is barely able to cross the blood--brain barrier, this is likely an effect in the periphery. The intra-cerebro-ventricular injection (rat) of 5-HT has minor effects on the mean arterial blood pressure but produces a decrease in heart rate ([@B114]; [@B131]; [@B30]). However, 5-HT can also cause generalized sympatho-excitation by stimulation of receptors at the site of sympathetic control (rostral ventrolateral medulla) and of receptor-mediated catecholamine release from adrenomedullary chromaffin cells. Neither systemic application nor intra-cerebro-ventricular injection allows identification of the specific receptor subtype involved ([Figure 1](#F1){ref-type="fig"}).

![The 5-HT~3~ receptor (center) is an excitatory cation channel (mainly Na^+^ and Ca^2+^), belonging to the cys-loop superfamily of ligand-gated ion channels closely related by homology to the nicotinic acetylcholine receptor. All other serotonin receptors are G-protein-coupled (GPCRs). The 5-HT subtypes 4, 6, and 7 are coupled to stimulatory G proteins (G~s~) responsible for increasing the cyclic AMP concentration. The subtypes 1 and 5 are coupled to inhibitory G proteins (G~i~) responsible for lowering the cyclic AMP concentration. The 5-HT~2~ receptors couple to G~q~ proteins activating phospholipase C (PLC) and ultimately increasing Ca^2+^ concentration ([@B64]). The effect of the activation of various serotonin receptors depends not only on the G protein they are coupled to but also on their localization. For instance, a serotonin receptor coupled to G~s~ localized on a GABAergic neuron will enhance inhibition, while a serotonin receptor coupled to G~i~ localized on a GABAergic neuron will reduce inhibition (inhibition of inhibition).](fnins-14-00629-g001){#F1}

Serotonin Receptors and Vagal Output {#S2}
====================================

5-HT~1A~ Receptors {#S2.SS1}
------------------

5-HT~1A~ receptors (G~i~) inhibit adenyl cyclase as their principal signaling mechanism ([@B64]). They are located both pre-synaptically and post-synaptically ([@B119]; [@B127]). Pre-synaptic 5-HT~1A~ auto-receptors located on cell bodies, when stimulated, lead to inhibition of firing of 5-HT neurons and are key components of a negative feedback loop (inhibitory auto-receptors), while pre-synaptic hetero-receptors located on GABAergic neurons reduce neurotransmitter release. By blocking 5-HT~1A~ auto-receptors at doses that are selective for them over post-synaptic 5-HT~1A~ receptors, it is possible to disinhibit 5-HT release. Stimulation of post-synaptic 5-HT~1A~ receptors on GABAergic neurons leads to hyperpolarization and reduced inhibition.

Adding complexity, the 5-HT~1A~ functions as a **hub receptor** in a number of iso- and hetero-receptor dimerizations ([@B13]). Receptor--receptor interaction (cross talk inhibition) takes place in the 5-HT iso-receptor complexes described (5-HT~1A~-5-HT~7~ and 5-HT~1A~-5-HT~2A~; [@B106]; [@B14], [@B13]).

Present knowledge indicates that activation of 5-HT~1A~ hetero-receptors enhances vagal activity by disinhibition of glutamatergic neurons \[reduction of (inhibitory) GABA release\]. Transgenic mice overexpressing 5-HT~1A~ receptors show prolonged episodes of bradycardia, and 5-HT~1A~ agonists induce bradycardia ([@B103]; [@B62]; [@B8]; [@B102]; [@B107]). 5-HT~1A~ receptor agonists produce miosis in humans ([@B137]). Measurement of pupil size seems to provide a valuable and sensitive index of 5-HT~1A~ receptor function ([@B38]).

5-HT~1A~ gene knockout animals showed increased fear and sympatho-activation under experimental conditions ([@B67]).

In conclusion, stimulation of 5-HT~1A~ receptors causes central sympatho-inhibition and an increase in cardiac vagal drive ([@B103]).

5-HT~2A~ Receptors {#S2.SS2}
------------------

5-HT~2A~ receptors \[G~q~; activation of phospholipase C→inositol triphosphate (IP~3~↑) and diacylglycerol (DAG↑)\] are expressed widely throughout the CNS and periphery ([@B57]). This is the main excitatory receptor subtype among the metabotropic 5-HT receptors. The receptor was first noted for its importance as a target of serotonergic psychedelic drugs such as LSD; later, it came back to prominence, because it was also found to be mediating, at least partly, the action of many antipsychotic drugs. Age-related reduction in the density of 5-HT~2A~ receptors is correlated with cognitive decline ([@B53]), and 5-HT~2A~ receptors are decreased in the prefrontal cortex of patients with Alzheimer's disease ([@B77]). In the periphery, it is highly expressed in platelets, cardiovascular system, fibroblasts, and neurons of the peripheral nervous system. Calcium entry through glutamate responsive NMDA channels subsequent to 5-HT~2A~ receptor activation dramatically affects both pre-synaptic and post-synaptic excitability of neurons in the DVN ([@B58]; [@B127]). Jordan assigns 5-HT~2A~ receptors a vagal activator effect ([@B62]). In contrast, others expressed the view that activation of 5-HT~2A~ leads to inhibition of parasympathetic synaptic transmission ([@B22]).

5-HT~2B~ Receptors {#S2.SS3}
------------------

5-HT~2B~ receptors (G~q~) are located both centrally and in the periphery. Agonists have been associated with endocardial fibrous tissue proliferation and (nor-fenfluramine) valvulopathy ([@B139]; [@B4]); antagonists lack (up to now) a clear therapeutic application. While [@B62] ascribes 5-HT~2B~ receptors a role in vagal activity, this does not appear to be prominent. Nevertheless, in NTS neurons receiving vagal afferent inputs, using ligands selective for the different 5-HT~2~ receptor subtypes, it was observed that activation of 5-HT~2A~ and 5-HT~2B~ receptors had predominantly excitatory effects while activation of 5-HT~2C~ receptors predominantly reduced neuronal firing.

5-HT~2C~ Receptors {#S2.SS4}
------------------

5-HT~2C~ receptors (G~q~) are structurally similar to 5-HT~2A~ receptors, and the two coexist in many brain regions and on the same neurons. Functionally, 5-HT~2A~ and 5-HT~2C~ are mostly antagonists. They play opposing facilitative and inhibitory roles. 5-HT~2C~ activation inhibits neurotransmitter (dopamine) release. Feeding, social interaction, sexual activity, and drugs (caffeine, nicotine, amphetamine, morphine, cocaine) all induce dopamine release, which is subject to inhibition by 5-HT~2C~. 5-HT~2C~ activation inhibits NTS neurons (vagal activity; [@B114]; [@B62]).

5-HT~3~ Receptors {#S2.SS5}
-----------------

5-HT~3~ receptors are the only ionotropic serotonin receptors. 5-HT~3~ receptors are located (mainly) on sensory vagal nerve endings and play a vital role for vagal afferent input from the gastrointestinal tract, lungs, and heart. The central terminals of vagal afferents exhibit 5-HT~3~ receptors that function to increase glutamatergic synaptic transmission to second-order neurons of the NTS within the brainstem ([@B16]). Experimental compounds with 5-HT~3~ blocking properties increase the heart rate by decreasing vagal afferent input and efferent output; this is compatible with data showing that 5-HT~3~ receptors excite vagal afferent neurons by a glutamate-dependent mechanism ([@B62]; [@B102]). Blockade of these receptors by 5-HT~3~ antagonists (setrons) is used clinically for control of emesis ([@B127]).

5-HT~4~ Receptors {#S2.SS6}
-----------------

5-HT~4~ receptors (G~s~; couple positively to adenylyl cyclase) control acetylcholine release; 5-HT~4~ antagonists have been proposed to treat an overactive bladder ([@B17]) while agonists (-pride) are gastro-kinetic agents. For a number of years (until its removal from the market due to concerns related to QT prolongation), cisapride was (more or less) successfully used to treat hiccups as part of a combination therapy with baclofen or gabapentin and omeprazole ([@B93]; [@B90]; [@B94]; [@B98]).

5-HT~5~ Receptors {#S2.SS7}
-----------------

5-HT~5~ receptors (G~i~ protein coupled) are virtually unexplored due to lack of selective ligands ([@B101]).

5-HT~6~ Receptors {#S2.SS8}
-----------------

5-HT~6~ receptors are G~s~ protein coupled and mediate excitatory neurotransmission. 5-HT~6~ receptors are expressed almost exclusively in the brain. Despite the 5-HT~6~ receptor having a functionally excitatory action (G~s~), it is largely co-localized with GABAergic neurons and produces an overall inhibition of brain activity ([@B138]).

More recently, it was recognized that 5-HT~6~ receptors modulate primarily GABA and glutamate levels, modulating the secondary release of other neurotransmitters ([@B66]). Most interestingly, it was recently demonstrated that 5-HT~6~ receptor antagonism reduces defecation in rats ([@B52]). This finding suggests an involvement of this receptor in the control of parasympathetic activity.

5-HT~7~ Receptors {#S2.SS9}
-----------------

5-HT~7~ receptors (G~s~ protein coupled) are expressed both centrally and in the periphery ([@B127]). Many---if not all---atypical antipsychotic drugs are also antagonists at this receptor. Defining the influence of this receptor on the vagus nerve is difficult, due to both species differences and the lack of selective agonists and antagonists. There is indication that 5-HT~7~ receptor protein is localized on vagal nerve fibers and that 5-HT~2~ and 5-HT~7~ receptors have opposite effects on vagal activity ([@B42]). Initial studies indicate that, in rodents, central 5-HT~7~ receptors play a facilitatory role in the reflex activation of vagal outflow to the heart ([@B65]) and that blocking either 5-HT~1A~ or 5-HT~7~ receptors attenuates bradycardias (i.e., increases heart rate), indicating that both subtypes have the ability to activate the vagus nerve ([@B62]; [@B102]). It was speculated that vagus activation was mediated by 5-HT~7~ receptors located in the NTS ([@B62]; [@B65]). In contrast, [@B42] report that 5-HT~7~ receptor activation suppresses the vagally induced bradycardia, suggesting the opposite, i.e., an inhibitory role of 5-HT~7~ receptors upon vagal activity. Moreover, the same group could demonstrate that 5-HT~7~ activation also stimulates the sympathetic outflow ([@B43]). [@B55] reported that blockade of 5-HT~2~ receptors uncovers 5-HT~7~ receptors' ability to inhibit the sympathetic drive in pithed rats, involving hyperpolarization due to the opening of ATP-sensitive K^+^ channels.

Complexity is added by 5-HT~1A~-5-HT~7~ co-expression and heterodimer formation. Hetero-dimerization (cross talk inhibition) decreases the ability of the 5-HT~1A~ receptor to induce hyperpolarization ([@B106]).

Summary {#S2.SS10}
-------

Taken together, it appears that the ability to increase vagus (efferent) output is associated with 5-HT~1A~, 5-HT~3~, 5-HT~4~, and possibly 5-HT~7~ agonists and with 5-HT~2C~ antagonists. The role of 5-HT~2A~ receptors is not clearly established ([Figure 2](#F2){ref-type="fig"}).

![Taken together, it appears that the ability to increase vagus (efferent) output is associated with 5-HT~1A~, 5-HT~3~, and 5-HT~4~ agonists and with 5-HT~2C~ antagonists. The role of 5-HT~7~ and 5-HT~2A~ receptors is not clearly established, but it appears possible that they also enhance vagal output.](fnins-14-00629-g002){#F2}

Purpose of the Work {#S3}
===================

Vagal mechanisms are operational in the occasional (transient) hiccup and most probably also in chronic singultus. Serotonergic neurotransmission is intricately related to vagal activity. Modulation of serotonergic neurotransmission influences vagal activity, offering possible explanations for the facilitation of singultus (vagal inhibition) by some drugs as well as for the ability of other compounds to suppress hiccups (vagal activation). We will discuss the effects of drugs that either stimulate or block 5-HT receptors upon vagal activity and hiccups. We hope the review will add to the understanding of the phenomenon singultus and possibly trigger a rethinking of the underlying biology of this condition.

Serotonin 5-HT~1A~ Agonists and Singultus {#S3.SS1}
-----------------------------------------

Activation of 5-HT~1A~ receptors enhances vagal activity; therefore, 5-HT~1A~ agonists could be useful in the control of chronic hiccups.

Flibanserin {#S3.SS2}
-----------

Flibanserin (approved for the treatment of premenopausal women with hypoactive sexual desire disorder) acts as a full agonist of the 5-HT~1A~ receptor and, with lower affinity, as an antagonist of the 5-HT~2A~ receptor ([@B15]). To our knowledge, no effect of flibanserin on singultus has been reported.

Anxiolytic Azapirones {#S3.SS3}
---------------------

**Tandospirone** was successfully employed for the treatment of intractable hiccups ([@B128]). However, other mechanisms and receptors may also come into play, since a major metabolite of tandospirone, 1-(2-pyrimidinyl)-piperazine (1-PP), is a centrally acting α~2~-adrenergic antagonist ([@B12]; [@B87]). Central α~2~ antagonism increases 5-HT release and availability ([@B112]). Therefore, the central α~2~-adrenergic antagonist **mirtazapine** (atypical antidepressant), can be considered an indirect 5-HT~1A~ receptor agonist. By additionally antagonizing 5-HT~2~ and 5-HT~3~ receptors ([@B5]), thereby funneling most of its action to the 1A subtype, mirtazapine mainly activates the 5-HT~1A~ receptor; it has also been successfully used for the treatment of intractable singultus ([@B32]; [@B25]).

In contrast, no beneficial effect upon singultus has been reported for **buspirone,** a tandospirone-like drug, which is a weaker partial 5-HT~1A~ agonist that has been available for nearly 30 years and is widely used. It has even been associated---albeit very rarely---with causing hiccups (\<1/1000 patients; [@B117]; [@B54]).

However, these differential effects of tandospirone and buspirone upon singultus may be due to differences in efficacies between these two compounds. Tandospirone and buspirone have similar affinities for the 5-HT~1A~ receptor (≈20--30 nM), but different efficacies. Buspirone has an efficacy (E~max~) of 20--50% at this receptor (as compared with 5-HT), while tandospirone has a higher E~max~ of 80%, closer to that of a full agonist ([@B134]; [@B126]).

Typical (haloperidol) and atypical (aripiprazole, olanzapine, risperidone, and brexpiprazole) **antipsychotics** also interact with the 5-HT~1A~ receptor. **Aripiprazole** is a partial 5-HT~1A~ agonist with comparable if not higher affinity (≈1--10 nM) than the spirones (5-HT~1A~ partial agonists), its efficacy being similar to tandospirone (E~max~ = 70%) ([@B115]; [@B28]).

In contrast, **olanzapine**, **risperidone,** and **haloperidol** have much lower affinities for this receptor (two orders of magnitude) and comparative efficacy (E~max~) in the low negative values (−15, −20, and −10, respectively), indicating antagonist/inverse agonist profiles ([@B85]).

**Aripiprazole** shows the strongest association of any antipsychotic drugs with hiccup induction. In contrast, olanzapine seems to be a successful antipsychotic agent in the context of singultus suppression ([@B2]; [@B108]). There is an abundance of reports on hiccups associated with aripiprazole treatment ([@B11]; [@B47]; [@B105]; [@B33]; [@B110]; [@B19]; [@B71]) and on persistent hiccups associated with switching antipsychotic treatment from risperidone to aripiprazole ([@B135]), from a typical antipsychotic drug of the thioxanthene class to aripiprazole ([@B36]), and from olanzapine to aripiprazole ([@B56]). In a patient treated with aripiprazole, singultus persisted, despite trials of metoclopramide and chlorpromazine; remission of hiccups occurred after discontinuation of aripiprazole ([@B117]).

**Pindolol,** a beta blocker with nanomolar affinity at 5-HT~1A~ receptors (Ki ≈ 10--30 nM) exhibits antagonist properties showing preferential action on somatodendritic 5-HT~1A~ auto-receptors with an efficacy of ≈20% relative to the endogenous agonist. Despite the functional antagonist profile, the drug to our knowledge has not been associated with hiccup induction ([@B21]).

Aripiprazole, buspirone, pindolol, and tandospirone, having similar effects upon the 5-HT~1A~ receptor, but quite different effects on singultus, do not provide support to the assumption that 5-HT~1A~ receptors play a pivotal role in the pathogenesis of hiccups. Equally unsupportive is the finding that inverse agonists/antagonists such as olanzapine do not seem to induce hiccups and, on the contrary, can be quite useful in treating them.

[@B128] suggested that 5-HT~1A~ agonists suppress hiccups by inhibiting phrenic nerve activity, while [@B117] proposed that 5-HT~1A~ partial agonists (functional antagonists) promote singultus by enhancing phrenic nerve motor activity.

**Chlorpromazine** (Ki ≈ 840 nM), for all practical purposes, has no effect at the 5-HT~1A~ receptor ([@B136]).

5-HT~2A~ Antagonists and Hiccups {#S3.SS4}
--------------------------------

Therapeutic efficacy of atypical antipsychotics and their metabolites depends on their high affinity (single digit nanomolar Ki) for and antagonist activity at this receptor subtype. As elaborated above, atypical antipsychotics can either induce or suppress hiccups, due to their affinity to other 5-HT receptor subtypes. With 5-HT~2A~ antagonism being a class-defining property of atypical antipsychotics, the influence of the 5-HT~2A~ receptor upon singultus pathogenesis can therefore not be easily evaluated. For comparison, chlorpromazine has a Ki ≈ 10 nM for this receptor.

5-HT~2C~ Agonists and Hiccups {#S3.SS5}
-----------------------------

Most typical (including chlorpromazine) and atypical antipsychotics are antagonists or inverse agonists at this receptor. In contrast, the previously mentioned atypical aripiprazole binds with nanomolar affinity at 5-HT~2C~ receptors (Ki ≈ 15--180 nM) and exhibits partial agonist properties with an efficacy Emax ≈ 80% relative to the endogenous agonist. **Lorcaserin**, marketed for weight loss, is the only selective 5-HT~2C~ receptor agonist clinically available (Ki ≈ 15 nM; Emax ≈ 40%). There are no reports regarding lorcaserin and hiccup. **Pimavanserin**, marketed for Parkinson's psychosis, is a 5-HT~2A~ and 5-HT~2C~ receptor antagonist (Ki ratio ≈ 1: 40; [@B121]). There are no reports regarding pimavanserin and singultus.

5-HT~3~ Antagonists and Hiccups {#S3.SS6}
-------------------------------

Antagonists **(-*setrons*)** are potent and highly selective competitive inhibitors with negligible affinity for other receptors. They are rapidly absorbed and penetrate the blood--brain barrier easily. Antiemetic efficacy results from a simultaneous action at peripheral and central 5-HT~3~ receptors.

Blockage of 5-HT~3~ receptors in the periphery reduces the activity of vagal afferents and would thus decrease efferent output; blocking 5-HT~3~ receptors centrally would also reduce efferent output. A single anecdotal mentioning of a negative impact of ***setrons*** on a patient with chronic hiccup has been published in 1992 ([@B92]). There are numerous anecdotal reports in the non-scientific literature claiming that setrons cause hiccups ([@B133]; [@B63]; [@B84]; [@B100]). Chlorpromazine has a very low affinity for this receptor ([@B136]). Taken together, these data suggest that 5-HT~3~ antagonists may facilitate singultus.

5-HT~7~ Antagonists and Hiccups {#S3.SS7}
-------------------------------

Initial studies suggest that activation of 5-HT~7~ receptors increases efferent vagal activity ([@B62]; [@B65]); more recent reports, however, indicate the opposite ([@B42]). Most antipsychotics (chlorpromazine, clozapine, risperidone, ziprasidone, paliperidone, pimozide, and amisulpride) are antagonists at the 5-HT~7~ receptors.

Nishikawa and his colleagues reported on a patient with intractable hiccups where haloperidol failed to provide relief, while in contrast, **risperidone** completely abolished the singultus shortly after administration ([@B86]). While both haloperidol and risperidone are antagonists with comparably low nanomolar affinity at D~2~ receptors, only risperidone blocks 5-HT~2C~ receptors and has an affinity, at least one order of magnitude higher (lower Ki) than haloperidol at 5-HT~2A~ and 5-HT~7~ receptors ([@B109]; [@B3]). The authors conclude that the ability of risperidone to suppress hiccups versus the failure of haloperidol to do so indicates that the serotonergic system may play a role in the pathophysiology of some hiccup forms ([@B86]). Notwithstanding such therapeutic successes, there are also case reports of risperidone inducing singultus ([@B23]).

**Pimozide** acts as an antagonist at D~2~-like receptors and the 5-HT~7~ receptor; it has the highest affinity of all the typical antipsychotic agents tested for the 5-HT~7~ receptor (Ki \< 1 nM; [@B109]). Pimozide is anecdotally reported to be clinically used to control not only nausea and vomiting but also intractable hiccups ([@B34]). However, there are also reports on pimozide causing hiccups ([@B79]).

**Amisulpride**, a benzamide antagonist of the dopamine D~2~ and D~3~ receptors and an antagonist of the 5-HT~2B~ and 5-HT~7~ receptors has been reported to induce singultus in a schizophrenic patient not sufficiently controlled on paliperidone ([@B23]). Paliperidone (9-OH-risperidone) has a receptor profile very similar to risperidone, with the difference of a lower affinity (antagonist) at the 5-HT~1A~ receptor. Compared with amisulpride, the affinity of the two for 5-HT~7~ is very similar (≈10 nM). Amisulpride has, however, no effect on other 5-HT receptors except 5-HT~2B~ (15 nM; [@B1]).

Aripiprazole, while commonly described as a partial agonist at 5-HT~7~, has a low intrinsic activity (Emax ≈ 2%), and hence is a functional antagonist of this receptor.

In summary, the observed pharmacological effects of medications upon hiccup can be attributed to a variety of receptors, including the 5-HT~7~ type. As long as there are no selective ligands of the 5-HT~7~ receptor that are clinically available, it is difficult to draw conclusions about the role of this receptor upon hiccup. Available data, however, suggest an influence of 5-HT~7~ receptors upon singultus pathogenesis and therapy.

Conclusion and Outlook {#S4}
======================

The overlap between maneuvers used to terminate paroxysmal supraventricular tachycardia, a not uncommon cardiac arrhythmia, and those employed to terminate bouts (paroxysms) of hiccups is striking. It suggests that activation of efferent vagal fibers can be therapeutic in both instances. While coincidence is obviously not proof of causality, it warrants nevertheless further investigations.

Taken together, it appears that the ability to increase vagus (efferent) output is associated with 5-HT~1A~, 5-HT~3~, and 5-HT~4~ agonists and with 5-HT~2C~ antagonists. The role of 5-HT~7~ receptors is not clearly established, but it appears possible that they also enhance vagal output.

Chlorpromazine does not display the ideal required profile for a vagus activator ([Table 1](#T1){ref-type="table"}).

###### 

Chlorpromazine, while without effect at 5-HT~1A~, 5-HT~3~, and 5-HT~4~ receptors, is a 5-HT~2A~, 5-HT~2C~, 5-HT~6~, and 5-HT~7~ antagonist and thus theoretically---at least from a serotonergic perspective---does not display the ideal required profile for a vagus activator. Affinities for the dopaminergic receptors are also provided.

                   5-HT (K*i* nM); antagonist                                                         
  ---------------- ------------------------------------ -------- -------- ------- --------------- --- ----
  Chlorpromazine   800+                                 10--15   15--25   600+    Not available   5   20
                                                                                                      
                   **Dopamine (K*i* nM); antagonist**                                                 
                   **1**                                **2**    **3**    **4**   **5**               
                                                                                                      
  Chlorpromazine   6--96                                2--12    2--10    8--56   Not available       

(

Kuoppamäki et al., 1995

;

Yonemura et al., 1998

;

Glennon, 2003

;

Kusumi et al., 2015

).

A review of the various drug actions does not warrant a definitive conclusion at this time. While painfully aware of the limitations of comparing receptor affinities/intrinsic activity values---even more so when obtained from different sources using different methodologies---and inferring biological effects based on such data, it is still the only practical option available ([@B31]; [@B27]; [@B120]). We nevertheless hope our work might add to the understanding of the phenomenon singultus and possibly trigger a rethinking of the underlying biology of this condition.
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